https://www.selleckchem.com/pr....oducts/namodenoson-c
OBJECTIVES Assessing medium-term functional results of a novel minimally-invasive treatment for lower urinary tract symptoms due to BPO with the second generation of the temporary implantable nitinol device (iTind; Medi-Tate Ltd®, Israel) 2-year follow-up of a single-arm, prospective, international multicenter study. Further, we aimed to identify preoperative baseline parameters predicting response to iTind treatment. METHODS Following local ethical committee approval in every participating centre, 81 men with symptomatic BPO
Like
Comment
Share
